We are live on ! Find out more
TAK icon

Takeda Pharmaceutical

387 hedge funds and large institutions have $3.65B invested in Takeda Pharmaceutical in 2019 Q1 according to their latest regulatory filings, with 298 funds opening new positions, 62 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,211% more first-time investments, than exits

New positions opened: 298 | Existing positions closed: 9

1,500% more funds holding in top 10

Funds holding in top 10: 1 → 16 (+15)

460% more capital inflows, than outflows

Capital inflows: $3.06B | Capital outflows: $547M

343% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 14

316% more funds holding

Funds holding: 93 → 387 (+294)

4.01% more ownership

Funds ownership: 1.73% → 5.74% (+4%)

1% less call options, than puts

Call options by funds: $94.4M | Put options by funds: $95.5M

Holders
387
Holders Change
+294
Holders Change %
+316.13%
% of All Funds
8.35%
Holding in Top 10
16
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+1,500%
% of All Funds
0.35%
New
298
Increased
62
Reduced
14
Closed
9
Calls
$94.4​M
Puts
$95.5​M
Net Calls
-⁠$1.07​M
Net Calls Change
-⁠$4.21​M

TAK Hedge Fund Activity: Q1 2019 in Review

387 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q1 2019, worth a combined $3.65B — up 300% from $912M a quarter earlier.

Buyers outnumbered sellers: 298 funds opened new TAK positions and 9 closed out — a net gain of 289 holders — while 62 added to existing stakes and 14 trimmed.

The largest buyer was Glenview Capital Management, opening a new position worth an estimated $525M. The largest seller was UBS Group, cutting an estimated $200M.

  • 387 institutional investors held Takeda Pharmaceutical (TAK) as of Q1 2019, up from 93 in Q4 2018.
  • Funds reported $3.65B of Takeda Pharmaceutical stock for Q1 2019, up 300% quarter-over-quarter.
  • 298 funds opened new Takeda Pharmaceutical positions in Q1 2019 and 9 closed out, a net change of +289 holders.
  • The largest Takeda Pharmaceutical buyer in Q1 2019 was Glenview Capital Management, an estimated $525M added.
  • The largest Takeda Pharmaceutical seller in Q1 2019 was UBS Group, an estimated $200M sold.

Based on aggregated 13F filings for Q1 2019.